PainReform (NASDAQ:PRFX) Earns Hold Rating from Maxim Group

Maxim Group restated their hold rating on shares of PainReform (NASDAQ:PRFX) in a research report report published on Thursday morning, Marketbeat reports.

PainReform Trading Down 8.9 %

PRFX opened at $0.64 on Thursday. PainReform has a 12-month low of $0.53 and a 12-month high of $20.16. The firm has a 50 day moving average of $0.59 and a two-hundred day moving average of $0.61. The firm has a market capitalization of $1.29 million, a PE ratio of -0.02 and a beta of 0.54.

PainReform (NASDAQ:PRFX) last issued its earnings results on Thursday, August 15th. The company reported ($0.40) earnings per share (EPS) for the quarter.

Institutional Trading of PainReform

An institutional investor recently raised its position in PainReform stock. Armistice Capital LLC raised its stake in PainReform Ltd. (NASDAQ:PRFX) by 76.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 276,000 shares of the company’s stock after acquiring an additional 120,000 shares during the quarter. Armistice Capital LLC owned approximately 13.60% of PainReform worth $132,000 at the end of the most recent reporting period. 37.28% of the stock is currently owned by institutional investors.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.